395 related articles for article (PubMed ID: 32725802)
1. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
3. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo.
Xiang S; Zou P; Tang Q; Zheng F; Wu J; Chen Z; Hann SS
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):589-599. PubMed ID: 29221985
[TBL] [Abstract][Full Text] [Related]
4. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
5. Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter.
Liu Y; Zhou J; Hu Y; Wang J; Yuan C
Mol Cell Biochem; 2017 Jan; 425(1-2):47-58. PubMed ID: 27830358
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
7. LINC00114 stimulates growth and glycolysis of esophageal cancer cells by recruiting EZH2 to enhance H3K27me3 of DLC1.
Qin J; Li Y; Li Z; Qin X; Zhou X; Zhang H; Li S
Clin Epigenetics; 2022 Apr; 14(1):51. PubMed ID: 35414117
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
Tripathi BK; Anderman MF; Bhargava D; Boccuzzi L; Qian X; Wang D; Durkin ME; Papageorge AG; de Miguel FJ; Politi K; Walters KJ; Doroshow JH; Lowy DR
Nat Commun; 2021 Dec; 12(1):6941. PubMed ID: 34862367
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Long Noncoding RNA HOTAIR and EZH2 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Human Breast Cancer Cells.
Han L; Zhang HC; Li L; Li CX; Di X; Qu X
Cancer Biother Radiopharm; 2018 Aug; 33(6):241-251. PubMed ID: 30048163
[TBL] [Abstract][Full Text] [Related]
11. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
Khan H; Ni Z; Feng H; Xing Y; Wu X; Huang D; Chen L; Niu Y; Shi G
Phytomedicine; 2021 Oct; 91():153706. PubMed ID: 34517264
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces autophagy, inhibits proliferation and invasion by downregulating AKT/mTOR signaling pathway in human melanoma cells.
Zhao G; Han X; Zheng S; Li Z; Sha Y; Ni J; Sun Z; Qiao S; Song Z
Oncol Rep; 2016 Feb; 35(2):1065-74. PubMed ID: 26573768
[TBL] [Abstract][Full Text] [Related]
13. Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101.
Wang Y; Xiang W; Wang M; Huang T; Xiao X; Wang L; Tao D; Dong L; Zeng F; Jiang G
Br J Pharmacol; 2014 Feb; 171(3):618-35. PubMed ID: 24490857
[TBL] [Abstract][Full Text] [Related]
14. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
Khan H; Jia W; Yu Z; Zaib T; Feng J; Jiang Y; Song H; Bai Y; Yang B; Feng H
Biomed Pharmacother; 2020 Aug; 128():110244. PubMed ID: 32464306
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA GAS5 promotes bladder cancer cells apoptosis through inhibiting EZH2 transcription.
Wang M; Guo C; Wang L; Luo G; Huang C; Li Y; Liu D; Zeng F; Jiang G; Xiao X
Cell Death Dis; 2018 Feb; 9(2):238. PubMed ID: 29445179
[TBL] [Abstract][Full Text] [Related]
16.
Guo J; Zhu H; Li Q; Dong J; Xiong W; Yu K
Aging (Albany NY); 2021 Apr; 13(8):11665-11677. PubMed ID: 33879635
[TBL] [Abstract][Full Text] [Related]
17. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
18. YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.
Chang LC; Lin HY; Tsai MT; Chou RH; Lee FY; Teng CM; Hsieh MT; Hung HY; Huang LJ; Yu YL; Kuo SC
Br J Pharmacol; 2014 Sep; 171(17):4010-25. PubMed ID: 24697523
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
Liu L; Fu Y; Zheng Y; Ma M; Wang C
Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
[TBL] [Abstract][Full Text] [Related]
20. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
